drugset / Trial / NCT03102489

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers

NCT03102489 ↗

Phase 1 Completed 18 enrolled Ivix LLX
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers.

Timeline

Start
2017-02-22
Primary completion
2017-06-21
Completion
2017-09-19

Drugs

EvaluationDrugModalityDoseRoute
Subject BP101 Unknown — Intranasal